Schizophrenia

• Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review (30 Sep 2024)
  
• The therapeutic role of Cannabidiol in mental health: a systematic review (24 Sep 2024)
  
• News Feature: Cannabis and the adolescent brain (24 Sep 2024)
  
• Cannabis and Psychosis: A Review of the Risk Factors Involved (17 Sep 2024)
  
• Association of early onset of cannabis, cigarette, other drug use and schizophrenia or psychosis (16 Sep 2024)
  
• Clinical and cognitive outcomes in first-episode psychosis: focus on the interplay between cannabis use and genetic variability in endocannabinoid receptors (03 Sep 2024)
  
• Terminal type-specific cannabinoid CB1 receptor alterations in patients with schizophrenia: A pilot study (02 Sep 2024)
  
• DNA methylation at cannabinoid type 1 and dopamine D2 receptor genes in saliva samples of psychotic subjects: Is there an effect of Cannabis use? (02 Sep 2024)
  
• Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders (25 Aug 2024)
  
• Changes in Expression of DNA-Methyltransferase and Cannabinoid Receptor mRNAs in Blood Lymphocytes After Acute Cannabis Smoking (25 Aug 2024)
  
• Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits (25 Aug 2024)
  
• New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders (21 Aug 2024)
  
• Therapeutic potential of the cannabinoid receptor 2 in neuropsychiatry (20 Aug 2024)
  
• Reversing the Psychiatric Effects of Neurodevelopmental Cannabinoid Exposure: Exploring Pharmacotherapeutic Interventions for Symptom Improvement (20 Aug 2024)
  
• Prenatal Cannabinoid Exposure: Emerging Evidence of Physiological and Neuropsychiatric Abnormalities (20 Aug 2024)
  
• Peripheral Endogenous Cannabinoid Levels Are Increased in Schizophrenia Patients Evaluated in a Psychiatric Emergency Setting (20 Aug 2024)
  
• Cannabinoid Receptor Interacting Protein 1a (CRIP1a) in Health and Disease (20 Aug 2024)
  
• Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls (20 Aug 2024)
  
• Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective (18 Aug 2024)
  
• Clinical characteristics of synthetic cannabinoid-induced psychosis in relation to schizophrenia: a single-center cross-sectional analysis of concurrently hospitalized patients (18 Aug 2024)
  
• Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy (18 Aug 2024)
  
• Quality of Life and a Surveillant Endocannabinoid System (05 Sep 2022)
  
• The Autism–Psychosis Continuum Conundrum: Exploring the Role of the Endocannabinoid System (31 Jul 2022)
  
• The therapeutic role of Cannabidiol in mental health: a systematic review - Journal of Cannabis Research (26 Jul 2022)